Drug Approval | June 28, 2024
Eugia SEZ’s injectable facility gets EIR from USFDA
The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated
The Unit has now received Establishment Inspection Report classifying the facility as Voluntary Action Indicated
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
The facility was inspected from May 7 to May 17, 2024
_256_384.jpg)
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
Austin assumes role from Glenn F. Tilton, who will continue to serve as an independent director
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Subscribe To Our Newsletter & Stay Updated
